Bone Solutions said today that it entered into a private label licensing agreement with Onkos Surgical for its OsteoCrete bone void-filling technology. Colleyville, Texas-based BSI’s OsteoCrete is an FDA 510(k)-cleared magnesium-based injectable, moldable solution designed to attaching ligaments and tendons to bone and bone to bone. Parsippany, N.J.-based Onkos Surgical intends to market OsteoCrete under the […]
Bone Solutions Inc.
WishBone Medical confirmed a private label distribution agreement with Bone Solutions, Inc. (BSI) for worldwide rights within pediatric orthopedics to license and sell OsteoCrete. OsteoCrete, a magnesium-based bone void filler, is designed to assist with bone repair and regeneration. It is the first device of its kind in the orthopedic market with 510(k) approval from […]
Tissue Genesis Inc. began clinical trials for a peripheral vascular disease (PVD) treatment composed of adipose-derived adult stem cell-coated vascular grafts. Adipose is more commonly know as fat, a tissue that the company believes has high-output regenerative medicine potential.
The Honolulu-based Tissue Genesis is the first to initiate an FDA-approved trial using the patient’s own fat-derived adult stem cells (ASCs) prepared at the point-of-care, according the company company.